Single Positive Endpoint Enough For Prana To Move Huntington’s Candidate To Pivotal Trial
Executive Summary
The PBT2 compound boosts executive function in first Phase II trial, but fails all other efficacy endpoints; however, past regulatory experience suggests that with few treatment options, one endpoint can do the trick in hard-to-treat Huntington’s disease.
You may also be interested in...
Revisiting Xenazine’s Extraordinary Review: A Study In FDA Flexibility
Unmet need is high in Huntington’s disease and the protracted review of Xenazine – the only drug cleared for the disease by FDA – suggests regulatory precedent for approval based on just one efficacy endpoint and with lots of development and safety baggage.
Top Neuroscience Partnering Opportunities: Seeking To Alter Treatment Paradigms
Neuroscience track at the Therapeutic Area Partnerships conferencewill feature novel candidates for Alzheimer’s, depression, traumatic brain injury, Fragile X syndrome and post-herpetic neuralgia.
A Silver Lining In Lilly’s Solanezumab Alzheimer’s Failure?
Drug fails all primary endpoints in two Phase III studies, following in the footsteps of Pfizer/Janssen’s bapineuzumab. But Lilly points to a secondary signal in pooled data as a sign of some effect on cognitive decline.